By Michele Maatouk
Date: Thursday 10 Oct 2019
(Sharecast News) - Belgian drug maker UCB has agreed to buy US-based clinical-stage biopharmaceuticals company Ra Pharmaceuticals for $2.1bn.
No recent information was found.
| GSK gets emerging markets boost with UCB deal | 24-Jan-2009 | Telegraph |
| UCB confident on drug go-ahead | 21-Aug-2007 | The Scotsman |
| Fellner shuffles Acambis board | 08-Mar-2007 | Telegraph |
| Deal speeds drugs sector consolidation | 26-Sep-2006 | The Herald |
No recent information was found.
No recent information was found.
| Currency | Euro |
| Share Price | 239.90 |
| Change Today | 0.10 |
| % Change | 0.04 % |
| 52 Week High | 260.20 |
| 52 Week Low | 129.35 |
| Volume | 141,416 |
| Shares Issued | 190.00m |
| Market Cap | 45,581m |
| Beta | 1.85 |
| Strong Buy | 6 |
| Buy | 11 |
| Neutral | 3 |
| Sell | 0 |
| Strong Sell | 1 |
| Total | 21 |

| Time | Volume / Share Price |
| 17:35 | 69 @ 239.90 |
| 17:35 | 64 @ 239.90 |
| 17:35 | 45 @ 239.90 |
| 17:35 | 103 @ 239.90 |
| 17:35 | 122 @ 239.90 |
You are here: research